person

Martin K.

Country
Germany
Department
Robert-Bosch-Krankenhaus Stuttgart, Abteilung Hämatologie, Onkologie, Studieneinheit ZIM2

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
101
Sites with multiple studies

Has run more than one trial at 101 of 260 partner sites.

Specializations

Acute Myeloid Leukemia

This investigator specializes in advancing treatment approaches for acute myeloid leukemia (AML), with particular focus on NPM1-mutated AML and innovative therapeutic combinations. Their research encompasses both newly diagnosed and relapsed/refractory cases.

  • Novel combination therapies
  • Molecular relapse monitoring
  • Targeted treatment strategies

The investigator explores integrative approaches using immunotherapy and conventional treatments for optimal patient outcomes.

Stem Cell Transplantation

The investigator has extensive expertise in allogeneic stem cell transplantation research, focusing on its application in various hematologic conditions including multiple myeloma and high-risk myelodysplastic syndromes.

  • Transplantation optimization
  • Graft-versus-host disease prevention
  • Conditioning regimens

Their work includes comparative studies of transplantation approaches versus conventional therapies.

Myeloid Disorders

The investigator conducts research in various myeloid conditions, including myelofibrosis and myelodysplastic syndromes. Their work extends to innovative therapeutic approaches for these challenging conditions.

  • Novel therapeutic combinations
  • Disease progression management
  • Treatment optimization strategies

The research encompasses both primary and secondary myeloid disorders with focus on improving patient outcomes.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.